Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma by Ito, Y et al.
Hepatocellular carcinoma (HCC) is a common neoplasm espe-
cially in East Asia and Africa. Although most HCCs are caused by
HBV infection in China (Beasley et al, 1981) and by intake of afla-
toxin in Africa (Uwaifo and Bababunmi, 1984), the dominant
cause in Japan is HCV (Saito et al, 1990). In spite of enormous
efforts to improve clinical treatment, HCC remains a major carci-
noma with high mortality. Poor differentiation, larger size, portal
invasion and intrahepatic metastasis are known to shorten disease-
free survival with this carcinoma. 
One of the most prominent parameters in evaluation of the
biological aggressiveness of carcinoma is the investigation of cell
behaviour. Growth factor receptors with tyrosine kinase activity are
known to contribute greatly to the regulation of cell behaviour
such as cell growth, proliferation and mortality (Ullrich and
Schlessinger, 1990; Cantley et al, 1991). The type I family of
growth factor receptors is the most prominent and is recognized as
a proto-oncogene family. The family consists of epidermal growth
factor receptor (EGF-R), c-erbB-2 and the more recently identified
c-erbB-3 and c-erbB-4 (Kraus et al, 1989; Plowman et al, 1993).
When specific ligands bind to a receptor of the family, the receptor
is activated by phosphorylation of the tyrosine residue in the
molecule (Ullrich and Schlessinger, 1990). It then forms a
dimer with another receptor of this family, causing activation by
transphosphorylation which contributes to a variety of growth
signal transductions (Pinkas-Kramarski et al, 1996). These recep-
tors share high sequence identity with each other and are coex-
pressed in various combinations in neoplasms. Thus far, of the four
receptors, the expression of EGF-R and c-erbB-2 has been investi-
gated in various neoplasms, including malignancies of the liver and
biliary tract (Brunt and Swanson, 1992; Collier et al, 1992;
Nakapoulou et al, 1994; Lee and Pirdas, 1995; Kira et al, 1997;
Terada et al, 1998). The other two receptors, c-erbB-3 and c-erbB-
4, have only been studied in depth for a few neoplasms (Sanidas et
al, 1993; Simpson et al, 1995; Shintani et al, 1995; Haugen et al,
1996; Travis et al, 1996; Bobrow et al, 1997; Bodey et al, 1997;
Chow et al, 1997; Ibrahim et al, 1997; Srinivasan et al, 1998, 2000;
Suo et al, 1998; Freiss et al, 1999; Haussler et al, 1999; Kapitanovic
et al, 2000; Kew et al, 2000), and little is known about their expres-
sion in hepatic malignancies. In this study, we investigated the
expression of all four components of this family in a large series of
HCC to evaluate their clinical significance and to identify the
factors reflecting the development of this carcinoma. 
MATERIALS AND METHODS 
Tissue specimens 
10% buffered formalin-fixed paraffin-embedded blocks of HCC
were prepared from 100 patients who had undergone surgery for
HCC. Informed consent was obtained from each patient. The char-
acteristics of these patients are summarized in Table 1. 
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The following antibodies were employed for immunohistochemistry,
with the concentrations given in parentheses. Sheep polyclonal anti-
body against EGF-R (06-129, 1:100) and mouse monoclonal
antibody against c-erbB-3 (clone 2F12 1:200) were purchased from
UBI (Lake Placid, NY, USA). A mouse monoclonal antibody against
c-erbB-2 (clone CB11 1:100) was obtained from Novocastra
(London, UK). A rabbit polyclonal antibody against c-erbB-4
(1:500) was established by our coworker and raised against synthetic
peptide (35–54 amino acid sequence) of c-erbB-4. We also employed
another polyclonal antibody against c-erbB-4 (sc-283, 1:50), which
recognizes the same epitope and found that the immunostaining
results for these two antibodies were fundamentally identical to
each other for the a limited number of cases examined for all diag-
nostic groups. Human placenta and skeletal muscle were adopted as
positive controls for antibodies against c-erbB-3 and c-erbB-4
(Srinivasan et al, 1998). A monoclonal antibody against Ki-67 (clone
MIB-1, 1:50) was obtained from Ylem (Rome, Italy). 
Immunohistochemistry 
Immunohistochemical study was performed using the avidin-biotin-
complex (ABC) method. Briefly, 4-mm slices of tissue section were
deparaffinized and endogenous peroxidase activity was blocked with
0.3% hydrogen peroxide and 0.1% sodium azide in distilled water for
15 min. Sections were then incubated with 0.03 mol L21 citrate buffer
(pH 6.0) and heated to 121˚C for 20 min in a pressure cooker except
for samples to study the immunohistochemistry of c-erbB-4. The
sections were next rinsed in phosphate-buffered saline pH 7.2 (PBS),
then 10% bovine serum (Wako, Osaka, Japan) was applied for 10
min to block the nonspecific reaction. The sections were incubated
with the primary antibody for 60 min at room temperature. After
rinsing in PBS, they were treated with biotinylated anti-sheep IgG
(Vector, Bulingame, CA, USA) at the concentration of 1:200 for
EGF-R, or biotinylated anti-mouse IgG (Amersham, London, UK) at
the concentration of 1:200 for c-erbB-2, c-erbB-3 and Ki-67, or
biotinylated anti-rabbit IgG (Dako, Copenhagen, Denmark) at the
concentration of 1:300 for c-erbB-4 for 15 min. After rinsing again
in PBS, the sections were allowed to react with the avidin-biotin
peroxidase complex (Dako, Copenhagen, Denmark) at the concen-
tration of 1:300 for 15 min. The peroxidase reaction was visualized
by incubating the sections with 0.02% 3,3¢-diaminobenzidine
tetrahydrochloride in 0.05 M Tris buffer (pH 7.6) with 0.01%
hydrogen peroxide. The sections were counterstained with haema-
toxylin. Sections for the negative control were prepared using normal
mouse serum instead of primary antibody. 
Immunohistochemical evaluation 
For immunohistochemical evaluation of EGF-R, c-erbB-2, 
c-erbB-3 and c-erbB-4, we regarded cells positive for these
proteins when the immunoreactivity was clearly observed in
them. We classified the cases as (++) when more than 50% of
the carcinoma cells were positive for these proteins, (+) when 10
to 50% of the cells were positive and (2) when less than 10% of
the cells were positive for these proteins. We counted positive cells
for Ki-67 by monitoring at least 500 HCC cells and calculated the
Ki-67 labelling index (LI). Ki-67 is widely accepted as a promin-
ent marker for cellular proliferation because it is expressed in all
cells except for those in the G0 phase (Sasaki et al, 1987). We
previously demonstrated that Ki-67 LI showed a prognostic signific-
ance for disease-free survival (DFS) of the patients, when the cut-
off value was set at 20% (Ito et al, 1999). Similar results were
obtained for the series of the present study and were subjected to
multivariate analyses of patient survival. 
Survival data 
Disease-free survival (DFS) data were analysed for the 85 patients
who had undergone curative surgery and could be followed after
surgery. They were followed for 5 to 80 months (mean 22.5 months).
Postoperative (DFS) curves were constructed by the Kaplan-Meier
method. 
Statistical analyses 
Values were expressed as mean ± S.D. The chi-squared test and
Kruskal-Wallis test followed by Dunn’s test of multiple comparisons
were employed for analyses of the relationship between the expres-
sion of the proteins and various clinicopathological parameters.
Univariate DFS data were analysed by the log-rank test. For multi-
variate analyses, we used the Cox proportional hazard model. A
P value less than 0.05 was considered to be statistically significant. 
RESULTS 
We performed immunostaining for EGF-R, c-erbB-2, c-erbB-3
and c-erbB-4 for 100 HCC cases and 84 noncancerous lesions
adjacent to carcinoma nests found in cases of chronic hepatitis
with or without liver cirrhosis. Profiles of the patients are shown in
Table 1. Various pathological classifications including degree of
differentiation conformed to The General Rules for the Clinical
and Pathological Study of Primary Liver Cancer of the Liver
Cancer Study Group of Japan (Liver Cancer Study Group of
Japan, 1992). The TNM staging we adopted in this study was
subject to that of the Liver Cancer Group of Japan and is identical
to the UICC criteria. Portal invasion and intrahepatic metastasis
were histologically diagnosed. 
EGF-R protein expression 
EGF-R immunoreactivity was observed mainly in the cell
membrane and occasionally and faintly in the cytoplasm of HCC
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Table 1 Profile of the 100 HCC cases used in this study 
Age (years) 62.3 ± 7.5
male 84
female 16
with 64 (59) 
without 36 (25) 
with 66 (59) 
without 22 (17) 
(unknown 12) (unknown 8) 
with 13 (10) 
without 76 (66) 
(unknown 11) (unknown 8) 
³III 34 
<III 66
Follow up time (months) 22.5 ± 17.2 
Figures in parenthesis indicate the profile of 84 patients whom noncancerous
lesions were immunohistochemically investigated for erbB receptor family.
Gender
Liver cirrhosis
HCV antibody
HBs antigen
Stagecells and noncancerous hepatocytes. The staining intensity was not
definitely different between them. Among the 100 HCC cases, 42
were classified as (++), 26 as (+) and 32 as (2) (Figure 1a). On the
other hand, only 13 (15.5%) of the 84 noncancerous lesions were
(+) for EGF-R and the remaining cases were (2). In 53 cases,
EGF-R was expressed more in HCC than in noncancerous lesions
(Table 2). EGF-R was expressed more frequently in HCC cases
with high Ki-67 LI (P < 0.0001), advanced stage (P = 0.0435),
intrahepatic metastasis (P = 0.0101) and poor differentiation (P =
0.0190) (Table 3A). Furthermore, EGF-R expression (++ vs +, 2)
showed a direct relationship with c-erbB-3 expression (++ vs
+, 2) (P = 0.0010). Furthermore, EGF-R expression (++,
+vs2) showed a prognostic significance (P = 0.0097) for DFS of
the patients in univariate analysis. 
erb-B family in hepatocellular carcinoma 1379
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Figure 1 Immunostaining of the erbB receptor family in HCC and noncancerouslesions. a) EGF-R expression in membranes of HCC cells. b) c-erbB-2
expression in membranes and cytoplasms of HCC cells. c,d) Cytoplasmic c-erbB-3 expression in c) noncancerous lesion and d) HCC. e,f) Cytoplasmic c-erbB-4
expression. e) Diffuse c-erbB-4 expression in noncancerous lesion whereas only equivocal staining in adjacent carcinoma nest which we do not regard
‘positive’. f) c-erbB-4 was diffusely expressed in this HCC case. Scale bars: a,b 28 mm; c, d, f 20 mm; e, 40 mm
E
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Fc-erbB-2 protein expression 
The immunoreactivity of this protein was observed as membranous
staining sometimes with faint cytoplasmic staining. In noncancerous
lesions, all cases were negative for this protein. In HCC, no cases
were classified as (++), 21 cases as (+) and the remaining 79 were
(2) (Figure 1b). As shown in Table 3B, we could not establish any
relationship between c-erbB-2 expression and the clinicopatho-
logical features as well as the prognosis of the patients. 
c-erbB-3 protein expression 
The c-erbB-3 protein was localized mainly in the cytoplasm of
the cells both in carcinoma cells and adjacent noncancerous
hepatocytes with the similar intensity. Of the 84 cases of
noncancerous lesions, 8 cases (9.5%) were (++), 24 cases
(28.6%) were (+) and 52 cases (61.9%) were (2) for this protein
(Figure 1c). Of the 100 HCC cases, 45, 39 and 16 were classi-
fied as (++), (+) and (2), respectively. In 64 cases (76.2%), c-
erbB-3 expression in HCC was greater than in noncancerous
lesions, whereas 14 cases (16.7%) and only 6 cases (7.1%)
expressed this receptor in HCC at a level equal to or less than
that in noncancerous lesions, respectively (Table 2). Although c-
erbB-3 expression was not related to the stage and portal inva-
sion, it was significantly linked to Ki-67 LI (P = 0.0344),
tumour size (P = 0.0202), intrahepatic metastasis (P = 0.0263)
and carcinoma differentiation (P = 0.0470) (Table 3C). c-erbB-3
expression (++ vs +, 2) showed a prognostic significance for
DFS (P = 0.0315) in univariate analysis. 
c-erbB-4 protein expression 
The immunoreactivity of c-erbB-4 was localized mainly in the
cytoplasm of HCC cells and noncancerous hepatocytes. The
immunoreactivity was generally clear in HCC cells and
noncancerous hepatocytes, but equivocal staining was some-
times observed in HCC cells which we did not regard as positive.
This protein was expressed, unlike the other three proteins, in
hepatocytes in noncancerous lesions with very high incidence,
that is, 53 cases (63.1%) were (++) and 21 cases (25.0%) were
(+) (Figure 1e). On the other hand, among the 100 HCC cases,
only 19 were (++), 42 were (+), and the remaining 39 were (2)
(Figure 1f). Only 3 (3.6%) of the 84 cases expressed more c-
erbB-4 protein in the HCC than in the adjacent noncancerous
lesions (Table 2). In 38 cases (45.2%), c-erbB-4 expression level
in the HCC was the same as in the adjacent noncancerous
lesions. Furthermore, in as many as 43 cases (51.2%), c-erbB-4
expression in HCC was even lower than in the noncancerous
lesions. As shown in Table 3D, c-erbB-4 staining in the carci-
noma was not linked to any clinicopathological features and
prognosis of the patients. 
In our series, carcinoma differentiation (poor vs moderate and
well) (P = 0.0072), tumour size (³ 5 cm vs <5 cm) (P = 0.0251),
portal invasion (P = 0.0665, borderline significance), intrahepatic
metastasis (P = 0.0012) and Ki-67 LI (³ 20% vs < 20%) (P =
0.0002) also affected the disease-free survival of the patients. We
next performed multivariate analysis by means of the Cox hazard
proportion model and found Ki-67 LI (P = 0.0405) and intra-
hepatic metastasis (P = 0.0434) to be independent prognostic
factors, whereas EGF-R and c-erbB-3 were not. 
DISCUSSION 
Our results showed that EGF-R was very frequently overexpressed
in HCC as compared to adjacent noncancerous lesions. Kira et al
have demonstrated that the overexpression of EGF-R in HCC was
related to carcinoma differentiation (Kira et al, 1997). In the
present study, we obtained more informative results probably
because of the larger number of cases examined. We found that
EGF-R overexpression is also correlated with high proliferating
activity, advanced stage, the presence of intrahepatic metastasis
and poor disease-free survival. The present study made it clearer
that EGF-R strongly reflects the biological aggressiveness of this
carcinoma and plays an important role in its progression. 
Our results for c-erbB-2 expression in HCC are similar to those
of previous studies with a smaller number of cases (Brunt and
Swanson, 1992; Collier et al, 1992; Nakopoulou et al, 1994). 
c-erbB-2 expression was not frequently found and does not
contribute to the malignant phenotype in HCC because it was not
related to any clinicopathological features including prognosis. Our
findings suggest that c-erbB-2 does not play an important role in
the progression of HCC, in contrast to several other malignancies
(Berchunk et al, 1990; Borg et al, 1990; Kameda et al, 1990; Kern
et al, 1990; Dugan et al, 1997; Yang et al, 1997). 
This is the first study on the expression of c-erbB-3 and c-erbB-
4 in HCC. In the investigation of the protein level for a large
number of cases, c-erbB-3 overexpression as compared to
noncancerous lesions was observed in 76.2% of the cases. Similar
studies have been performed on a few other carcinomas. For
example, Sanidas et al demonstrated that the c-erbB-3 protein was
always expressed in both gastric carcinoma and the adjacent
mucosa, but the expression level was usually higher in the carci-
noma (Sanidas et al, 1993). Travis et al observed that breast carci-
noma expressed c-erbB-3 more intensely and diffusely than the
adjacent normal glands which were usually weakly or moderately
positive for this protein (Travis et al, 1996). Haugen et al showed
that normal follicles of the thyroid were all negative for c-erbB-3,
whereas all types of thyroid carcinoma expressed this protein with
very high incidence (Haugen et al, 1996). The results of these
studies including ours are similar in that they show c-erbB-3
expression to be more diffuse and/or more intense in the carcinoma
nest than in normal or benign lesions. 
Our study also showed that c-erbB-3 expression in HCC is signif-
icantly related to some important markers of carcinoma progression,
which are also predictors of recurrence, such as proliferating
activity, tumour size, intrahepatic metastasis and carcinoma differ-
entiation. Furthermore, c-erbB-3 itself, to some extent, affects
disease-free survival. Similar results were obtained for breast carci-
noma, i.e., c-erbB-3 is related to tumour size and tumour type prog-
nostic group (Travis et al, 1996), and for colorectal carcinoma, i.e.,
cases without c-erbB-3 expression show a favourable outcome for
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Table 2 Expression of erbB family in HCC 
Less than  Equal to  Greater than 
noncancerous noncancerous noncancerous
lesion lesion lesion
EGF-R 0 31 53 
c-erbB-2 0 68 16 
c-erbB-3 6 14 64 
c-erbB-4 43 38 3 erb-B family in hepatocellular carcinoma 1381
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Table 3 The relationship between the expression of erbB family and various clinicopathological features of 100 HCC patients 
A. EGF-R expression 
++ (n = 42) + (n = 26) 2 (n = 32) 
Ki-67 LI 40.4 ± 20.1 24.9 ± 17.3 20.6 ± 15.1 *P < 0.0001 
Stage ³III 19 8 7 P = 0.0435 
<III 23 18 25 (++vs+, 2) 
Tumour size ³5 cm 22 14 9 NS 
<5 cm 20 12 23
Portal invasion with 19 9 8 NS 
without 23 17 24
Intrahepatic metastasis with 15 5 3 P = 0.0101 
without 27 21 29 (++ vs +, 2) 
Carcinoma differentiation poor 16 9 1 P = 0.0190 
moderate or well 26 17 31 (++ vs +, 2) 
c-erbB-2 expression + 13 3 5
2 92 3 2 7N S
c-erbB-3 expression ++ 27 9 9 P = 0.0010 
+, 2 15 17 23 
++ 6 6 7 (++ vs+, 2 )
c-erbB-4 expression + 25 17 20 NS 
2 11 3 5
*This analysis was done by Kruskal-Wallis test. P = 0.0008 for ++vs+ and <0.0001 for ++vs2 by Dunn’s test. 
B. c-erbB-2 expression  + (n = 21) 2 (n = 79) 
Ki-67 LI 31.4 ± 21.0 29.7 ± 19.5 NS 
Stage ³III 8 26
<III 13 53 NS 
Tumour size ³5 cm 11 34
<5 cm 10 45 NS 
Portal invasion with 8 28
without 13 51 NS 
Intrahepatic metastasis with 3 20
without 18 59 NS
Carcinoma differentiation poor 5 21
moderate or well 16 58  NS
++ 11 34
c-erbB-3 expression + 5 34
2 5 11 NS 
++ 3 16
c-erbB-3 expression + 13 49
2 51 4N S
C. c-erbB-3 expression  ++ (n = 45) + (n = 39) 2 (n = 16) 
Ki-67 LI 31.4 ± 19.2 33.1 ± 20.7 18.6 ± 13.2 * P = 0.0344 
Stage ³III 19 11 4 NS 
<III 26 28 12
Tumour size ³5 cm 26 16 3 P = 0.0202 
<5 cm 19 23 13 (++, +vs2) 
Portal invasion with 20 11 5 NS 
without 25 28 11 
Intrahepatic metastasis with 15 6 2 P = 0.0263 
without 30 33 14 (++, +vs2) 
Carcinoma differentiation poor 15 10 1 P = 0.0470 
moderate or well 30 29 15 (++, +vs2) 
c-erbB-4 expression ++ 11 7 1
+ 25 24 13 NS 
2 98 1  
*This analysis was done by Kruskal-Wallis test. P = 0.0261 for ++vs- and 0.0261 for +vs - by Dunn’s test. 
D. c-erbB-4 expression  ++ (n = 19) + (n = 62) 2 (n = 19)
Ki-67 LI 29.3 ± 14.2 29.9 ± 21.2 30.9 ± 21.3 NS 
Stage ³III 8 21 5 NS 
<III 11 41 14
Tumour size ³5 cm 11 27 7 NS 
<5 cm 8 35 12
Portal invasion with 9 19 8 NS 
without 10 43 11
Intrahepatic metastasis with 2 18 3 NS 
without 17 44 16 
Carcinoma differentiation poor 6 13 7 NS 
moderate or well 13 49 12DFS of the patients (Kapitanovic et al, 2000). On the other hand,
such relationships have not been found with other neoplasms such
as carcinoma of the esophagus (Freiss et al, 1999), stomach (Sanidas
et al, 1993) and ovary (Simpson et al, 1995). In the prostate, a recent
study demonstrated the frequent expression of c-erbB-3 in prostatic
intraepithelial neoplasia as well as prostatic carcinoma, suggesting
that c-erbB-3 plays a role in the carcinogenesis of this carcinoma
(Haussler et al, 1999). Therefore, the role of c-erbB-3 may not be
uniform for all neoplasms, and HCC displays c-erbB-3 expression
as a typical characteristic. 
c-erbB-4 protein expression in carcinoma nests was usually equal
to or less than in noncancerous lesions. A similar tendency was
obtained for other carcinomas such as those of the breast, colon,
ovary, bronchus, and head and neck (Srinivasan et al, 1998), although
the opposite tendency was obtained for thyroid carcinoma (Haugen
et al, 1996), endometrial carcinoma (Srinivasan et al, 1999), astrocy-
toma (Srinivasan et al, 1998) and cholangiocellular carcinoma (Ito et
al, in press). Among them, breast carcinoma has been comparatively
well-studied for c-erbB-4 expression, which is stronger in more
differentiated breast carcinoma cell lines than in the more aggressive
ones (Plowman et al, 1993; Suo et al, 1998), in normal epithelia than
in carcinomas (Srinivasan et al, 1998, 2000; Suo et al, 1998), and in
cases with steroid receptors than in those without them (Riese et al,
1996). Furthermore, more recent studies demonstrated that c-erbB-4
expression is associated with a more differentiated histological
phenotype (Kew et al, 2000; Srinivasan et al, 2000). On the other
hand, our present study with HCC demonstrated that c-erbB-4
expression is not linked to any clinicopathological features including
disease-free survival of the patients. Therefore, the clinical signific-
ance of c-erbB-4 in HCC is not clear and still needs to be elucidated.
Some ligands of c-erbB-4 such as heparin binding epidermal growth
factor-like growth factor (HB-EGF), batacellulin, epiregulin and
neuregulins have been identified (Riese et al, 1996; Elenius et al,
1997; Komurasaki et al, 1997; Zhang et al, 1997). Investigations
regarding the expression of these ligands, which have been partially
done for endometrial carcinoma (Srinivasan et al, 1999), and
regarding the status of signal transduction via c-erbB-4 when the
ligands do or do not bind to this receptor and when heterodimeriza-
tion occurs between c-erbB-4 and other type I receptor family, should
help clarify the significance of c-erbB-4 in HCC. 
In this study, we found cytoplasmic immunoreactivity especially
of c-erbB-3 and c-erbB-4, although they are also transmembranous
glycoprotein receptors. The significance of this finding is still
unclear, but one possible explanation is the delayed turnover of these
receptors in the cytoplasm. Baulida et al demonstrated that EGF-R is
internalized and rapidly down- regulated subject to lysosomal degra-
dation when it forms a complex with EGF, while such a ligand-
induced mechanism could not be observed in other type I receptors
(Baulida et al, 1996). Furthermore, of the type I family, EGF-R only
has internalization codes within its cytoplasmic domain (Chang et al,
1993). These findings may, at least in part, explain the cytoplasmic
localization of c-erbB-3 and c-erbB-4 in contrast to the dominant
membranous localization of EGF-R. Alternatively, these proteins
may accumulate in the cytoplasm as a latent form in larger quantity
than EGF-R and c-erbB-2 before they become active at the cell
membrane. This point needs to be further specified by future studies
from different aspects. A recent study has demonstrated the nuclear
localization of c-erbB-4 (Srinivasan et al, 1999, 2000; Kew et al,
2000), but we did not find this in our HCC series. 
In the present study, we also demonstrated that EGF-R expres-
sion is directly linked to c-erbB-3 expression. This phenomenon
was found in previous in vitro studies as well as a clinical study
using surgical specimens for transitional cell carcinoma (Kim et al,
1994; Soltoff et al, 1994; Chow et al, 1997). Further studies are
needed to find whether the relationship is due to heterodimeriza-
tion of these receptors in this carcinoma. 
In summary, the present study showed that, of the four kinds
of type 1 family receptors, EGF-R and c-erbB-3 have roles in the
progression of HCC. Further studies are needed to elucidate the
meaning of the less frequent expression of c-erbB-2 and reduced
expression of c-erbB-4 in HCC as compared to noncancerous lesions. 
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